EGFR and small cell lung carcinoma: Activation of alternative pathways, such as Met amplification and IGF1R overexpression, has been implicated in resistance to EGFR-TKIs in non-small cell lung cancer cells bearing EGFR mutation (12, 14), and these molecules bypass the original oncogenic pathway to confer resistance to previously effective therapy.